Ensysce Biosciences Past Earnings Performance
Past criteria checks 0/6
Ensysce Biosciences's earnings have been declining at an average annual rate of -24%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 6.5% per year.
Key information
-24.0%
Earnings growth rate
-2.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -6.5% |
| Return on equity | n/a |
| Net Margin | -476.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Ensysce Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -11 | 5 | 0 |
| 30 Sep 23 | 3 | -13 | 5 | 0 |
| 30 Jun 23 | 3 | -20 | 5 | 0 |
| 31 Mar 23 | 3 | -26 | 6 | 0 |
| 31 Dec 22 | 3 | -25 | 7 | 0 |
| 30 Sep 22 | 3 | -30 | 7 | 0 |
| 30 Jun 22 | 4 | -38 | 22 | 0 |
| 31 Mar 22 | 4 | -31 | 20 | 0 |
| 31 Dec 21 | 4 | -30 | 19 | 0 |
| 30 Sep 21 | 2 | -19 | 18 | 0 |
| 30 Jun 21 | 2 | 0 | 1 | 0 |
| 31 Mar 21 | 3 | 0 | 1 | 0 |
| 31 Dec 20 | 4 | 0 | 1 | 0 |
| 31 Dec 19 | 2 | -10 | 7 | 0 |
Quality Earnings: ENSC is currently unprofitable.
Growing Profit Margin: ENSC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ENSC is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.
Accelerating Growth: Unable to compare ENSC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENSC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ENSC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.